Endostatin/collagen XVIII is increased in cerebrospinal fluid after severe traumatic brain injury

Hao Chen, Li-Xia Xue, He-Li Cao, Shi-Wen Chen, Yan Guo, Wen-Wei Gao, Shi-Ming Ju, Heng-Li Tian, Hao Chen, Li-Xia Xue, He-Li Cao, Shi-Wen Chen, Yan Guo, Wen-Wei Gao, Shi-Ming Ju, Heng-Li Tian

Abstract

Recent studies have suggested that endogenous angiogenesis inhibitor endostatin/collagen XVIII might play an important role in the secondary brain injury following traumatic brain injury (TBI). In this study, we measured endostatin/collagen XVIII concentrations serially for 1 week after hospitalization by using the enzyme-linked immunosorbent assay method in the cerebrospinal fluid (CSF) of 30 patients with TBI and a Glasgow Coma Scale (GCS) score of 8 or less on admission. There was a significant trend toward increased CSF levels of endostatin after TBI versus control from 72 h after injury. In patients with GCS score of 3-5, CSF endostatin concentration was substantially higher at 72 h after injury than that in patients with GCS score of 6-8 (P < 0.05) and peaked rapidly at day 5 after injury, but decreased thereafter. The CSF endostatin concentration in 12 patients with an unfavorable outcome was significantly higher than that in 18 patients with a favorable outcome at day 5 (P = 0.043) and day 7 (P = 0.005) after trauma. Receiver operating characteristic curve analysis suggested a reliable operating point for the 7-day CSF endostatin concentration predicting poor prognosis to be 67.29 pg/mL. Our preliminary findings provide new evidence that endostatin/collagen XVIII concentration in the CSF increases substantially in patients with sTBI. Its dynamic change may have some clinical significance on the judgment of brain injury severity and the assessment of prognosis. This trial is registered with the ClinicalTrials.gov Identifier: NCT01846546.

Figures

Figure 1
Figure 1
Elevation of CSF endostatin/collagen XVIII concentrations following TBI at days 3, 5, and 7 but not day 1. (a) Bar graph showing the time course of endostatin/collagen XVIII concentrations in CSF of severe TBI patients 1 day, 3 days, 5 days, and 7 days after injury, compared with that in control patients without TBI. (b) Bar graph showing CSF endostatin/collagen XVIII concentrations in two GCS score groups on days 1, 3, 5, and 7 after injury. Each bar represents the mean and standard error of the mean of all samples over all time points. Statistical analysis was performed by Student's t-test or Mann-Whitney test. *P < 0.05 and **P < 0.01 compared with their respective controls.
Figure 2
Figure 2
Graphs showing correlations between endostatin/collagen XVIII concentrations in CSF and 1-month prognosis situation and 6-month outcome in the 30 study patients with severe TBI. Data are expressed as mean ± SEM values. *P < 0.05 and **P < 0.01 compared with their respective controls.
Figure 3
Figure 3
Receiver operating characteristic (ROC) curve to predict the possibility of unfavorable outcome at 6 months after trauma by measuring the CSF levels of endostatin/collagen XVIII. The value of 67.29 pg/mL at day 7 was considered the cutoff point, with the sensitivity and specificity of 75.0% and 83.3%, respectively.

References

    1. Pandya NM, Dhalla NS, Santani DD. Angiogenesis—a new target for future therapy. Vascular Pharmacology. 2006;44(5):265–274.
    1. Sköld MK, Risling M, Holmin S. Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration. European Journal of Neuroscience. 2006;23(1):21–34.
    1. Morgan R, Kreipke CW, Roberts G, Bagchi M, Rafols JA. Neovascularization following traumatic brain injury: possible evidence for both angiogenesis and vasculogenesis. Neurological Research. 2007;29(4):375–381.
    1. Nag S, Takahashi JL, Kilty DW. Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma. Journal of Neuropathology and Experimental Neurology. 1997;56(8):912–921.
    1. Nag S, Eskandarian MR, Davis J, Eubanks JH. Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury. Journal of Neuropathology and Experimental Neurology. 2002;61(9):778–788.
    1. Italiano JE, Jr., Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. Blood. 2008;111(3):1227–1233.
    1. Shore PM, Jackson EK, Wisniewski SR, et al. Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery. 2004;54(3):605–612.
    1. Sköld MK, von Gertten C, Sandberg-Nordqvist AC, Mathiesen T, Holmin S. VEGF and VEGF receptor expression after experimental brain contusion in rat. Journal of Neurotrauma. 2005;22(3):353–367.
    1. Gong D, Zhang S, Liu L, et al. Dynamic changes of vascular endothelial growth factor and angiopoietin-1 in association with circulating endothelial progenitor cells after severe traumatic brain injury. Journal of Trauma-Injury, Infection and Critical Care. 2011;70(6):1480–1484.
    1. Mueller CA, Schluesener HJ, Fauser U, Conrad S, Schwab JM. Lesional expression of the endogenous angiogenesis inhibitor endostatin/collagen XVIII following traumatic brain injury (TBI) Experimental Neurology. 2007;208(2):228–237.
    1. Zhang ZY, Zhang Z, Fauser U, Artelt M, Burnet M, Schluesener HJ. Dexamethasone transiently attenuates up-regulation of endostatin/collagen XVIII following traumatic brain injury. Neuroscience. 2007;147(3):720–726.
    1. Deininger MH, Meyermann R, Schluesener HJ. Endostatin/collagen XVIII accumulates in patients with traumatic brain injury. Journal of Neurotrauma. 2006;23(7):1103–1110.
    1. The Brain Trauma Foundation. Guidelines for the management of severe head injury. Introduction. Journal of Neurotrauma. 1996;13(11):643–645.
    1. Teasdale GM, Pettigrew LEL, Wilson JTL, Murray G, Jennett B. Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. Journal of Neurotrauma. 1998;15(8):587–597.
    1. Wenzel D, Schmidt A, Reimann K, et al. Endostatin, the proteolytic fragment of collagen XVIII, induces vasorelaxation. Circulation Research. 2006;98(9):1203–1211.
    1. Seppinen L, Sormunen R, Soini Y, Elamaa H, Heljasvaara R, Pihlajaniemi T. Lack of collagen XVIII accelerates cutaneous wound healing, while overexpression of its endostatin domain leads to delayed healing. Matrix Biology. 2008;27(6):535–546.
    1. Bloch W, Huggel K, Sasaki T, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. The FASEB Journal. 2000;14(15):2373–2376.
    1. Mueller CA, Conrad S, Schluesener HJ, Pietsch T, Schwab JM. Spinal cord injury-induced expression of the antiangiogenic endostatin/collagen XVIII in areas of vascular remodelling. Journal of Neurosurgery. 2007;7(2):205–214.
    1. Benezra R, Rafii S. Endostatin’s endpoints—deciphering the endostatin antiangiogenic pathway. Cancer Cell. 2004;5(3):205–206.
    1. Tao Q, Spring SC, Terman BI. Comparison of the signaling mechanisms by which VEGF, H2O2, and phosphatase inhibitors activate endothelial cell ERK1/2 MAP-kinase. Microvascular Research. 2005;69(1-2):36–44.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir